1 Killed, 3 Injured in Crash on Highway 154 Near Painted Cave Road

Posted on April 10, 2020April 10, 2020 by Staff Writer

Brian Watana Dul Arrested for DUI in Fatal Santa Barbara Accident

Santa Barbara, CA (April 8, 2020) – One person was killed and three others were injured in a crash in Santa Barbara. The fatal accident occurred on the evening of April 8 on Highway 154.

A Mazda and a Toyota 4Runner collided on Highway 154, near Painted Cave Road, when one of the vehicles T-boned the other. One person was trapped inside a vehicle. They were extricated by emergency crews.

Four people were taken to a local hospital. One person – a male passenger in the Mazda – later died. Three others suffered minor to moderate injuries. The driver of the Toyota, identified as 22-year-old Brian Watana Dul from Goleta, was arrested for DUI and vehicular manslaughter

Our heartfelt condolences go out to the friends and loved ones of the victim.

Nadrich & Cohen is an active donor and supporter of several local MADD (Mothers Against Drunk Driving) chapters throughout California.

#Santa Barbara

#93105

Free Police Report Request

We offer free consultation. No office visit required, we will get back to you within 24 hours.

What can we do for you?

Answer your legal question.

Provide a Free Case Evaluation.

Schedule an appointment.

Why Choose Us?

Available 24/7

Trusted Since 1990

Local to You

Recovered $350,000,000

5 Star Reviews

Free Case Evaluation

VIP Service

No Win, No Fee

Latest Law Post

May 22, 2020

Johnson & Johnson Discontinues Talc-Based Baby Powder

baby powder new Johnson & Johnson discontinued its talc-based baby powders in the United States and Canada because thousands of lawsuits claiming it was contaminated with asbestos created a sales decline.

May 18, 2020

FDA Issues Warnings To Two Manufacturers Of Breast Implants

The U.S. Food and Drug Administration (FDA) just issued warning letters to two manufacturers of breast implants for failing to comply with regulatory requirements. The FDA sent a warning letter to Allergan for failure to comply with requirements to conduct post-approval studies assessing the risks and long-term safety of two separate breast implant models. Both breast implant models were voluntarily recalled last year. The FDA also sent a warning letter to Ideal Implant Incorporated. That letter was sent for failing to comply with adverse event reporting requirements and current good manufacturing practice requirements. The letter was prompted by an inspection which was conducted earlier in 2020.